Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 8/20 | 0.41 |
| ▸ | RAB9A | P51151 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322878 | 0.87 | KMT2A (0.53) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL2325145 | 0.84 | HTT (0.39) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL2329635 | 0.84 | FLT1 (0.43) | SMN1; SMN2HTTMAPTNPC1RAB9A | |
| SCHEMBL1549242 | 0.80 | ERCC5 (0.49) | SMN1; SMN2HTTKMT2AMEN1NPC1 | |
| SCHEMBL10357072 | 0.80 | LMNA (0.51) | SMN1; SMN2KMT2AMEN1MAPTNPC1 | |
| SCHEMBL2322311 | 0.77 | SMN1; SMN2 (0.44) | TAS1R3TAS1R1TAS1R2HSD11B1SMN1; SMN2 | |
| SCHEMBL27755384 | 0.74 | HSD11B1 (0.46) | TAS1R3TAS1R1TAS1R2HSD11B1SMN1; SMN2 | |
| SCHEMBL2648128 | 0.73 | HSD11B1 (0.54) | TAS1R3TAS1R1TAS1R2HSD11B1SMN1; SMN2 | |
| SCHEMBL581464 | 0.73 | HSD11B1 (0.54) | TAS1R3TAS1R1TAS1R2HSD11B1SMN1; SMN2 | |
| SCHEMBL2324606 | 0.73 | CES2 (0.49) | RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | TAS1R3 3044/4885TAS1R1 1712/4885TAS1R2 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.